MCA Stability Tool

Find stability recommendations for tablets and capsules.

Product Search

Stability Notes

There are no stability notes available for this medicine.

Stability Notes

There are no stability notes available for this medicine.

Stability Notes

Not suitable for compliance aid: packaged with a desiccant.

Provenance

This compatibility recommendation is derived from Concerta XL 18mg tablets (Janssen-Cilag Ltd).

Stability Notes

Not suitable for compliance aid: packaged with a desiccant.

Provenance

Compatibility recommendation derived from Concerta XL 27mg tablets (Janssen-Cilag Ltd)

Stability Notes

Not suitable for compliance aid: packaged with a desiccant.

Provenance

Compatibility recommendation derived from Concerta XL 36mg tablets (Janssen-Cilag Ltd).

Stability Notes

Not suitable for compliance aid: packaged with a desiccant.

Provenance

Compatibility recommendation derived from Concerta XL 54mg tablets (Janssen-Cilag Ltd).

Stability Notes

Store in airtight containers and protect from light.

Provenance

This compatibility recommendation is derived from Thiamine 100mg tablets (Accord Healthcare Ltd).

Stability Notes

Store in airtight containers and protect from light.

Provenance

This compatibility recommendation is derived from Thiamine 50mg tablets (Accord Healthcare Ltd).

Print this list

Medicines suitable for use in MCAs, although use is likely to be off-label.  Keep medicines in MCAs for the shortest time necessary. Generally, up to 5 weeks maximum unless otherwise specified, or consider up to 8 weeks if the MCA is airtight (sealed).  Consider the risk to the individual from potency loss or dose variability, particularly with unsealed devices.  Monitor for any changes in therapeutic effect or increased adverse effects after MCA initiation.
There are concerns about stability and/or there is a lack of stability data available. These medicines can theoretically be used in MCAs, although use is likely to be off-label.  Mitigation measures may need to be considered.  Keep medicines in MCAs for the shortest time necessary.  Generally, up to 5 weeks maximum unless otherwise specified, or consider up to 8 weeks if the MCA is airtight (sealed). Consider the risk to the individual from potency loss or dose variability, particularly with unsealed devices. Monitor for any changes in therapeutic effect or increased adverse effects after MCA initiation.
Medicines under this category are not suitable for use in MCAs.
These medicines have not been reviewed by SPS.